Does the company plan to provide any forward‑looking statements or updates on pipeline progress during the event? | DERM (Aug 07, 2025) | Candlesense

Does the company plan to provide any forward‑looking statements or updates on pipeline progress during the event?

Based on the press release you provided, Journey Medical’s announcement about ringing the Nasdaq closing bell focuses on two specific celebratory items:

  1. The company’s 4‑year anniversary as a Nasdaq‑listed public company, and
  2. The commercial launch of Emrosi™ (40 mg Minocycline Hydrochloride Modified‑Release Capsules) for rosacea.

The release does not mention any agenda items beyond those two points. In particular, there is no language indicating that management will issue forward‑looking statements, provide an earnings outlook, or give updates on other pipeline programs during the bell‑ringing ceremony.

What this means for your question

  • Forward‑looking statements: The notice does not state that the event will include any forward‑looking statements. While many Nasdaq bell‑ringing events do include brief remarks that may contain forward‑looking information, the only content disclosed in this release is the anniversary celebration and the Emrosi launch.

  • Pipeline progress updates: The release does not reference any pipeline candidates other than Emrosi (which is already commercial‑stage). No updates on pre‑clinical or other clinical programs are mentioned.

In short: The press release does not indicate that Journey Medical plans to provide forward‑looking statements or pipeline progress updates during the August 11, 2025 Nasdaq closing‑bell ceremony. If such remarks are intended, they have not been disclosed in the information you provided.